Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Head and Neck Cancer

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 140 articles: HTML format

Single Articles

May 2024
1. PENG X, Zhao H, Ye L, Hou F, et al
   Biomarker identification and risk prediction model development for differentiated thyroid carcinoma lung metastasis based on primary lesion proteomics.
   Clin Cancer Res. 2024 May 9. doi: 10.1158/1078-0432.CCR-23-3806.
   PubMed     Abstract available
   
   
   
2. TANG T, Zhou Z, Chen M, Li N, et al
   Plasma Metabolic Profiles-Based Prediction of Induction Chemotherapy Efficacy in Nasopharyngeal Carcinoma: Results of a Bidirectional Clinical Trial.
   Clin Cancer Res. 2024 May 7. doi: 10.1158/1078-0432.CCR-23-3608.
   PubMed     Abstract available
   
   
   
3. PRENEN H, Deva S, Keam B, Lindsay CR, et al
   Phase II study to determine the anti-tumor activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in esophageal cancer.
   Clin Cancer Res. 2024 May 6. doi: 10.1158/1078-0432.CCR-23-2677.
   PubMed     Abstract available
   
   
   
4. ROSS RB, Gadwa J, Yu J, Darragh LB, et al
   PPARalpha Agonism Enhances Immune Response to Radiotherapy While Dietary Oleic Acid Results in Counteraction.
   Clin Cancer Res. 2024;30:1916-1933.
   PubMed     Abstract available
   
   
   
5. LIU Y, Yan W, Hu C, Huang X, et al
   Optimizing Cervical Target Volume in Patients with Nasopharyngeal Cancer Based On Nodal Drainage Distance.
   Clin Cancer Res. 2024;30:1801-1810.
   PubMed     Abstract available
   
   
   April 2024
6. SHANNON NB, Iyer NG
   Unveiling Liquid Gold: Lymph as an HPV Marker in OPSCC to Guide Treatment Decisions.
   Clin Cancer Res. 2024;30:1223-1225.
   PubMed     Abstract available
   
   
   
7. EARLAND N, Semenkovich NP, Ramirez RJ, Gerndt SP, et al
   Sensitive MRD Detection from Lymphatic Fluid after Surgery in HPV-Associated Oropharyngeal Cancer.
   Clin Cancer Res. 2024;30:1409-1421.
   PubMed     Abstract available
   
   
   
8. READ ML, Brookes K, Zha L, Manivannan S, et al
   Combined Vorinostat and Chloroquine Inhibit Sodium-Iodide Symporter Endocytosis and Enhance Radionuclide Uptake In Vivo.
   Clin Cancer Res. 2024;30:1352-1366.
   PubMed     Abstract available
   
   
   March 2024
9. ZANONI DK, Demetrio De Souza Franca P, Valero C, Peterson G, et al
   A Prospective Double-Blinded Comparison of Reflectance Confocal Microscopy with Conventional Histopathology for In Vivo Assessment in Oral Cancer.
   Clin Cancer Res. 2024 Mar 25. doi: 10.1158/1078-0432.CCR-23-1361.
   PubMed     Abstract available
   
   
   
10. SWIECICKI PL, Bellile E, Dragovic AF, McHugh J, et al
    Upfront neck dissection for treatment selection and improvement in quality of life as a novel treatment paradigm for deintensification in HPV+ OPSCC.
    Clin Cancer Res. 2024 Mar 22. doi: 10.1158/1078-0432.CCR-23-3247.
    PubMed     Abstract available
    
    
    
11. KIM CG, Hong MH, Kim D, Lee BH, et al
    A phase II open-label randomized clinical trial of preoperative durvalumab or durvalumab plus tremelimumab in resectable head and neck squamous cell carcinoma.
    Clin Cancer Res. 2024 Mar 8. doi: 10.1158/1078-0432.CCR-23-3249.
    PubMed     Abstract available
    
    
    
12. JAKOBSEN K, Carlander AF, Todsen T, Melchiors J, et al
    Mesenchymal Stem/Stromal Cell Therapy for Radiation-Induced Xerostomia in Previous Head and Neck Cancer Patients: A Phase 2 Randomised, Placebo-Controlled Trial.
    Clin Cancer Res. 2024 Mar 5. doi: 10.1158/1078-0432.CCR-23-3675.
    PubMed     Abstract available
    
    
    February 2024
13. SAITO S, Kono M, Nguyen HCB, Egloff AM, et al
    Targeting Dendritic Cell Dysfunction to Circumvent anti-PD1 Resistance in Head and Neck Cancer.
    Clin Cancer Res. 2024 Feb 19. doi: 10.1158/1078-0432.CCR-23-3477.
    PubMed     Abstract available
    
    
    January 2024
14. MEHANNA H, Rapozo D, von Zeidler SV, Harrington KJ, et al
    Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study.
    Clin Cancer Res. 2024;30:356-367.
    PubMed     Abstract available
    
    
    
15. LECHNER MG, Brent GA
    A New Twist on a Classic: Enhancing Radioiodine Uptake in Advanced Thyroid Cancer.
    Clin Cancer Res. 2024 Jan 10. doi: 10.1158/1078-0432.CCR-23-3503.
    PubMed     Abstract available
    
    
    
16. VON WITZLEBEN A, Ellis M, Thomas GJ, Hoffmann TK, et al
    Tumor-Infiltrating CD103+ Tissue-Resident Memory T Cells and CD103-CD8+ T Cells in HNSCC Are Linked to Outcome in Primary but not Metastatic Disease.
    Clin Cancer Res. 2024;30:224-234.
    PubMed     Abstract available
    
    
    
17. PENA-OYARZUN D, Flores T, Torres VA, Quest AFG, et al
    Inhibition of PORCN Blocks Wnt Signaling to Attenuate Progression of Oral Carcinogenesis.
    Clin Cancer Res. 2024;30:209-223.
    PubMed     Abstract available
    
    
    December 2023
18. KIM YH, Yoon SJ, Kim M, Kim HH, et al
    Integrative multi-omics analysis reveals different metabolic phenotypes based on molecular characteristics in thyroid cancer.
    Clin Cancer Res. 2023 Dec 13. doi: 10.1158/1078-0432.CCR-23-2025.
    PubMed     Abstract available
    
    
    November 2023
19. NGAMPHAIBOON N, Pattaranutaporn P, Lukerak S, Siripoon T, et al
    A Phase I Study of the CDK4/6 Inhibitor, Palbociclib in Combination with Cetuximab and Radiotherapy (IMRT) for Locally Advanced Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2023 Nov 20. doi: 10.1158/1078-0432.CCR-23-2303.
    PubMed     Abstract available
    
    
    
20. OU X, Zhai R, Wei W, Chen J, et al
    Induction Toripalimab And Chemotherapy For Organ Preservation In Locally Advanced Laryngeal And Hypopharyngeal Cancer: A Single-Arm Phase 2 Clinical Trial.
    Clin Cancer Res. 2023 Nov 13. doi: 10.1158/1078-0432.CCR-23-2398.
    PubMed     Abstract available
    
    
    
21. SHEN C, Shi X, Wen D, Zhang Y, et al
    Comprehensive DNA Methylation Profiling of Medullary Thyroid Carcinoma: Molecular Classification, Potential Therapeutic Target, and Classifier System.
    Clin Cancer Res. 2023 Nov 6. doi: 10.1158/1078-0432.CCR-23-2142.
    PubMed     Abstract available
    
    
    October 2023
22. PIFER PM, Yang L, Kumar M, Xie T, et al
    FAK drives resistance to therapy in HPV-negative head and neck cancer in a p53-dependent manner.
    Clin Cancer Res. 2023 Oct 11. doi: 10.1158/1078-0432.CCR-23-0964.
    PubMed     Abstract available
    
    
    
23. FU H, Huang J, Zhao T, Wang H, et al
    Fibroblast Activation Protein-Targeted Radioligand Therapy with 177Lu-EB-FAPI for Metastatic Radioiodine Refractory Thyroid Cancer: First-in-Human, Dose-Escalation Study.
    Clin Cancer Res. 2023 Oct 6. doi: 10.1158/1078-0432.CCR-23-1983.
    PubMed     Abstract available
    
    
    
24. KLEMPNER SJ, Lee KW, Shitara K, Metges JP, et al
    ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
    Clin Cancer Res. 2023;29:3882-3891.
    PubMed     Abstract available
    
    
    
25. JAKOBSEN KK, Bendtsen SK, Pallisgaard N, Friborg J, et al
    Liquid Biopsies with Circulating Plasma HPV-DNA Measurements-A Clinically Applicable Surveillance Tool for Patients with HPV-Positive Oropharyngeal Cancer.
    Clin Cancer Res. 2023;29:3914-3923.
    PubMed     Abstract available
    
    
    September 2023
26. DERRY JMJ, Burns C, Frazier JP, Beirne E, et al
    Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment.
    Clin Cancer Res. 2023;29:3813-3825.
    PubMed     Abstract available
    
    
    
27. DUKE ES, Bradford D, Marcovitz M, Amatya AK, et al
    FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors.
    Clin Cancer Res. 2023;29:3573-3578.
    PubMed     Abstract available
    
    
    
28. LEE MS, Kaseb AO, Pant S
    The Emerging Role of Circulating Tumor DNA in Non-Colorectal Gastrointestinal Cancers.
    Clin Cancer Res. 2023;29:3267-3274.
    PubMed     Abstract available
    
    
    August 2023
29. CHI Y, Zheng X, Zhang Y, Shi F, et al
    Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase â…¡ Trial.
    Clin Cancer Res. 2023 Aug 18:CCR-22-3406. doi: 10.1158/1078-0432.CCR-22-3406.
    PubMed     Abstract available
    
    
    
30. HEFT NEAL ME, Brenner JC
    Prognosis to Radiation Unlocked: How Hypoxia Methylome May Hold the Key in HNSCC.
    Clin Cancer Res. 2023;29:2954-2956.
    PubMed     Abstract available
    
    
    
31. TAWK B, Rein K, Schwager C, Knoll M, et al
    DNA-Methylome-Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy.
    Clin Cancer Res. 2023;29:3051-3064.
    PubMed     Abstract available
    
    
    
32. NIU Z, Sun P, Liu H, Wei P, et al
    Functional Genetic Variants in TGFbeta1 and TGFbetaR1 in miRNA-Binding Sites Predict Outcomes in Patients with HPV-positive Oropharyngeal Squamous Cell Carcinoma.
    Clin Cancer Res. 2023;29:3081-3091.
    PubMed     Abstract available
    
    
    
33. JACOBS MT, Wong P, Zhou AY, Becker-Hapak M, et al
    Memory-like differentiation, tumor targeting monoclonal antibodies, and chimeric antigen receptors enhance natural killer cell responses to head and neck cancer.
    Clin Cancer Res. 2023 Aug 9:CCR-23-0156. doi: 10.1158/1078-0432.CCR-23-0156.
    PubMed     Abstract available
    
    
    
34. BEYAERT SP, Loriot AE, Huyghe ND, Goebbels RM, et al
    Tumor microenvironment modifications induced by afatinib in squamous cell carcinoma of the head and neck - a window-of-opportunity study (EORTC90111-24111).
    Clin Cancer Res. 2023 Aug 2:CCR-23-0645. doi: 10.1158/1078-0432.CCR-23-0645.
    PubMed     Abstract available
    
    
    July 2023
35. MORI K, Notsu A, Miura K, Onozawa Y, et al
    MEDI0457 Plus Durvalumab in HPV-associated HNSCC-Letter.
    Clin Cancer Res. 2023;29:2735.
    PubMed    
    
    
    
36. AGGARWAL C, Gong M, Kumar R
    MEDI0457 Plus Durvalumab in HPV-associated HNSCC-Response.
    Clin Cancer Res. 2023;29:2736.
    PubMed    
    
    
    
37. MARON SB, Chatila W, Walch H, Chou JF, et al
    Determinants of survival in HER2+ metastatic esophagogastric cancer.
    Clin Cancer Res. 2023 Jul 5:CCR-22-3769. doi: 10.1158/1078-0432.CCR-22-3769.
    PubMed     Abstract available
    
    
    
38. HONDERMARCK H, Jiang CC
    Time to Introduce Nerve Density in Cancer Histopathologic Assessment.
    Clin Cancer Res. 2023;29:2342-2344.
    PubMed     Abstract available
    
    
    June 2023
39. SHER DJ, Moon DH, Vo D, Wang J, et al
    Efficacy and quality-of-life following involved nodal radiotherapy for head and neck squamous cell carcinoma: the INRT-AIR phase II clinical trial.
    Clin Cancer Res. 2023 Jun 26:CCR-23-0334. doi: 10.1158/1078-0432.CCR-23-0334.
    PubMed     Abstract available
    
    
    
40. HU H, Ng TSC, Kang M, Scott E, et al
    Thyroid cancers exhibit oncogene-enhanced macropinocytosis that is restrained by IGF1R and promotes albumin-drug-conjugate response.
    Clin Cancer Res. 2023 Jun 8:CCR-22-2976. doi: 10.1158/1078-0432.CCR-22-2976.
    PubMed     Abstract available
    
    
    
41. BIKAS A, Ahmadi S, Pappa T, Marqusee E, et al
    Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes.
    Clin Cancer Res. 2023 Jun 1:OF1-OF8. doi: 10.1158/1078-0432.CCR-23-0278.
    PubMed     Abstract available
    
    
    May 2023
42. LIN Y, Qin S, Yang H, Shi F, et al
    Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer.
    Clin Cancer Res. 2023 May 15:CCR-22-3613. doi: 10.1158/1078-0432.CCR-22-3613.
    PubMed     Abstract available
    
    
    April 2023
43. LEBOULLEUX S, Do Cao C, Zerdoud S, Attard M, et al
    A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E Mutated Differentiated thyroid Cancer.
    Clin Cancer Res. 2023 Apr 19:CCR-23-0046. doi: 10.1158/1078-0432.CCR-23-0046.
    PubMed     Abstract available
    
    
    
44. PEREZ-PACHECO C, Schmitd LB, Furgal A, Bellile EL, et al
    Increased Nerve Density Adversely Affects Outcome in Oral Cancer.
    Clin Cancer Res. 2023 Apr 11:OF1-OF12. doi: 10.1158/1078-0432.CCR-22-3496.
    PubMed     Abstract available
    
    
    February 2023
45. GULATI S, Crist M, Riaz MK, Takiar V, et al
    Durvalumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, non-randomized, phase-2 clinical trial.
    Clin Cancer Res. 2023 Feb 21:CCR-22-3886. doi: 10.1158/1078-0432.CCR-22-3886.
    PubMed     Abstract available
    
    
    
46. WILDSMITH S, Li W, Wu S, Stewart R, et al
    Tumor Mutational Burden as a Predictor of Survival With Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2023 Feb 20:CCR-22-2765. doi: 10.1158/1078-0432.CCR-22-2765.
    PubMed     Abstract available
    
    
    
47. BOUCAI L, Saqcena M, Kuo F, Grewal RK, et al
    Genomic and transcriptomic characteristics of metastatic thyroid cancers with exceptional responses to radioactive iodine therapy.
    Clin Cancer Res. 2023 Feb 13:CCR-22-2882. doi: 10.1158/1078-0432.CCR-22-2882.
    PubMed     Abstract available
    
    
    
48. WILS LJ, Poell JB, Brink A, Evren I, et al
    Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation.
    Clin Cancer Res. 2023;29:602-613.
    PubMed     Abstract available
    
    
    
49. GE H, Ferris RL, Wang JH
    Cetuximab Responses in Patients with HNSCC Correlate to Clonal Expansion Feature of Peripheral and Tumor-Infiltrating T Cells with Top T-Cell Receptor Clonotypes.
    Clin Cancer Res. 2023;29:647-658.
    PubMed     Abstract available
    
    
    January 2023
50. OSMAN AA, Arslan E, Bartels M, Michikawa C, et al
    Dysregulation and epigenetic reprogramming of NRF2 signaling axis promote acquisition of cisplatin resistance and metastasis in Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2023 Jan 23:CCR-22-2747. doi: 10.1158/1078-0432.CCR-22-2747.
    PubMed     Abstract available
    
    
    
51. MASCARELLA MA, Olonisakin TF, Rumde P, Vendra V, et al
    Response to neoadjuvant targeted therapy in operable head and neck cancer confers survival benefit.
    Clin Cancer Res. 2023 Jan 3:CCR-22-1768. doi: 10.1158/1078-0432.CCR-22-1768.
    PubMed     Abstract available
    
    
    December 2022
52. HORIBA MN, Casak SJ, Mishra-Kalyani PS, Roy P, et al
    FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic Disease.
    Clin Cancer Res. 2022;28:5244-5248.
    PubMed     Abstract available
    
    
    
53. MEZGHANI N, Yao A, Vasilyeva D, Kaplan N, et al
    Molecular Subtypes of Head and Neck Cancer in Patients of African Ancestry.
    Clin Cancer Res. 2022 Dec 12:CCR-22-2258. doi: 10.1158/1078-0432.CCR-22-2258.
    PubMed     Abstract available
    
    
    
54. AGGARWAL C, Saba NF, Algazi A, Sukari A, et al
    Safety and Efficacy of MEDI0457 Plus Durvalumab in Patients With Human Papillomavirus-associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2022 Dec 1:CCR-22-1987. doi: 10.1158/1078-0432.CCR-22-1987.
    PubMed     Abstract available
    
    
    
55. NATHAN CO, Hayes DN, Karrison T, Harismendy O, et al
    A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck.
    Clin Cancer Res. 2022;28:5040-5048.
    PubMed     Abstract available
    
    
    
56. SHI W, Fijardo M, Bruce JP, Su J, et al
    CD8+ Tumor-Infiltrating Lymphocyte Abundance Is a Positive Prognostic Indicator in Nasopharyngeal Cancer.
    Clin Cancer Res. 2022;28:5202-5210.
    PubMed     Abstract available
    
    
    November 2022
57. RODRIGUEZ-RAMIREZ C, Zhang Z, Warner KA, Herzog AE, et al
    p53 Inhibits Bmi-1-driven Self-Renewal and Defines Salivary Gland Cancer Stemness.
    Clin Cancer Res. 2022;28:4757-4770.
    PubMed     Abstract available
    
    
    
58. FERGUSON AL, Sharman AR, Allen RO, Ye T, et al
    High-Dimensional and Spatial Analysis Reveals Immune Landscape-Dependent Progression in Cutaneous Squamous Cell Carcinoma.
    Clin Cancer Res. 2022;28:4677-4688.
    PubMed     Abstract available
    
    
    October 2022
59. CABANILLAS ME, Busaidy NL, Sherman SI
    Redifferentiation Therapy-Returning to Our Roots in a Post-Kinase Inhibitor World.
    Clin Cancer Res. 2022;28:4164-4166.
    PubMed     Abstract available
    
    
    
60. COLEVAS AD
    HPV DNA as a Biomarker in Oropharyngeal Cancer: A Step in the Right Direction.
    Clin Cancer Res. 2022;28:4171-4172.
    PubMed     Abstract available
    
    
    
61. BERGER BM, Hanna GJ, Posner MR, Genden EM, et al
    Detection of Occult Recurrence Using Circulating Tumor Tissue Modified Viral HPV DNA among Patients Treated for HPV-Driven Oropharyngeal Carcinoma.
    Clin Cancer Res. 2022;28:4292-4301.
    PubMed     Abstract available
    
    
    September 2022
62. PAUDEL S, Warner BE, Wang R, Adams-Haduch J, et al
    Serological profiling using an Epstein-Barr virus mammalian expression library identifies EBNA1 IgA as a pre-diagnostic marker for nasopharyngeal carcinoma.
    Clin Cancer Res. 2022 Sep 27. pii: 709488. doi: 10.1158/1078-0432.CCR-22-1600.
    PubMed     Abstract available
    
    
    
63. MIERZWA ML, Aryal M, Lee C, Schipper M, et al
    Randomized Phase II study of Physiologic MRI-directed Adaptive Radiation Boost in Poor Prognosis Head and Neck Cancer.
    Clin Cancer Res. 2022 Sep 15. pii: 709219. doi: 10.1158/1078-0432.CCR-22-1522.
    PubMed     Abstract available
    
    
    
64. YU M, Moinova HR, Willbanks A, Cannon VK, et al
    Novel DNA Methylation Biomarker Panel for Detection of Esophageal Adenocarcinoma and High-Grade Dysplasia.
    Clin Cancer Res. 2022;28:3761-3769.
    PubMed     Abstract available
    
    
    
65. ROHRER BLEY C, Wolf F, Goncalves Jorge P, Grilj V, et al
    Dose- and Volume-Limiting Late Toxicity of FLASH Radiotherapy in Cats with Squamous Cell Carcinoma of the Nasal Planum and in Mini Pigs.
    Clin Cancer Res. 2022;28:3814-3823.
    PubMed     Abstract available
    
    
    August 2022
66. QURESHY Z, Li H, Zeng Y, Rivera J, et al
    STAT3 activation as a predictive biomarker for ruxolitinib response in head and neck cancer.
    Clin Cancer Res. 2022 Aug 5. pii: 707467. doi: 10.1158/1078-0432.CCR-22-0744.
    PubMed     Abstract available
    
    
    
67. LEE YJ, van den Berg NS, Duan H, Azevedo EC, et al
    89Zr-panitumumab combined with 18F-FDG-PET improves detection and staging of head and neck squamous cell carcinoma.
    Clin Cancer Res. 2022 Aug 5. pii: 707464. doi: 10.1158/1078-0432.CCR-22-0094.
    PubMed     Abstract available
    
    
    
68. YOON HH, Dong H, Shi Q
    Impact of PD-1 Blockade in Nonresponders: Pitfalls and Promise.
    Clin Cancer Res. 2022;28:3173-3175.
    PubMed     Abstract available
    
    
    
69. HONG X, Li Q, Li J, Chen K, et al
    CircIPO7 Promotes Nasopharyngeal Carcinoma Metastasis and Cisplatin Chemoresistance by Facilitating YBX1 Nuclear Localization.
    Clin Cancer Res. 2022 Aug 2. pii: 707414. doi: 10.1158/1078-0432.CCR-22-0991.
    PubMed     Abstract available
    
    
    July 2022
70. ZHU M, Chen C, Foster NR, Hartley C, et al
    Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction.
    Clin Cancer Res. 2022;28:3021-3031.
    PubMed     Abstract available
    
    
    
71. JUNG HA, Park KU, Cho S, Lim J, et al
    A Phase II Study of Nivolumab Plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11).
    Clin Cancer Res. 2022 Jul 12. pii: 706988. doi: 10.1158/1078-0432.CCR-22-1238.
    PubMed     Abstract available
    
    
    
72. SCHMITD LB, Perez-Pacheco C, Bellile EL, Wu W, et al
    Spatial and Transcriptomic Analysis of Perineural Invasion in Oral Cancer.
    Clin Cancer Res. 2022 Jul 12:OF1-OF16. doi: 10.1158/1078-0432.CCR-21-4543.
    PubMed     Abstract available
    
    
    
73. LYNGGAARD CD, Gronhoj C, Jensen SB, Christensen R, et al
    Long-term Safety of Treatment with Autologous Mesenchymal Stem Cells in Patients with Radiation-Induced Xerostomia: Primary Results of the MESRIX Phase I/II Randomized Trial.
    Clin Cancer Res. 2022;28:2890-2897.
    PubMed     Abstract available
    
    
    June 2022
74. ZHANG Z, Wu B, Peng G, Xiao G, et al
    Neoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Clinical Trial.
    Clin Cancer Res. 2022 Jun 29:OF1-OF9. doi: 10.1158/1078-0432.CCR-22-0666.
    PubMed     Abstract available
    
    
    
75. SIHAG S, Nussenzweig SC, Walch HS, Hsu M, et al
    The Role of the TP53 Pathway in Predicting Response to Neoadjuvant Therapy in Esophageal Adenocarcinoma.
    Clin Cancer Res. 2022;28:2669-2678.
    PubMed     Abstract available
    
    
    
76. DUKE ES, Barone AK, Chatterjee S, Mishra-Kalyani PS, et al
    FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer.
    Clin Cancer Res. 2022 Jun 9. pii: 704846. doi: 10.1158/1078-0432.CCR-22-0873.
    PubMed     Abstract available
    
    
    
77. LEE KW, Van Cutsem E, Bang YJ, Fuchs CS, et al
    Association of Tumor Mutational Burden with Efficacy of Pembrolizumab{plus minus}Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study.
    Clin Cancer Res. 2022 Jun 3. pii: 699374. doi: 10.1158/1078-0432.CCR-22-0121.
    PubMed     Abstract available
    
    
    
78. LEDDON JL, Gulati S, Haque S, Allen C, et al
    Phase 2 trial of adjuvant nivolumab following salvage resection in patients with recurrent squamous cell carcinoma of the head and neck.
    Clin Cancer Res. 2022 Jun 2. pii: 699312. doi: 10.1158/1078-0432.CCR-21-4554.
    PubMed     Abstract available
    
    
    May 2022
79. WANG W, Lozar T, Golfinos AE, Lee D, et al
    Stress Keratin 17 Expression in Head and Neck Cancer Contributes to Immune Evasion and Resistance to Immune-Checkpoint Blockade.
    Clin Cancer Res. 2022 May 27:OF1-OF16. doi: 10.1158/1078-0432.CCR-21-3039.
    PubMed     Abstract available
    
    
    
80. SCHMITD LB, Perez-Pacheco C, Bellile EL, Wu W, et al
    Spatial and Transcriptomic Analysis of Perineural Invasion in Oral Cancer.
    Clin Cancer Res. 2022 May 26. pii: 699248. doi: 10.1158/1078-0432.CCR-21-4543.
    PubMed     Abstract available
    
    
    
81. WEBER M, Kersting D, Riemann B, Brandenburg T, et al
    Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancer With MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study.
    Clin Cancer Res. 2022 May 20. pii: 699089. doi: 10.1158/1078-0432.CCR-22-0437.
    PubMed     Abstract available
    
    
    
82. DENEKA AY, Baca Y, Serebriiskii IG, Nicolas E, et al
    Association of TP53 and CDKN2A Mutation Profile with Tumor Mutation Burden in Head and Neck Cancer.
    Clin Cancer Res. 2022;28:1925-1937.
    PubMed     Abstract available
    
    
    April 2022
83. LE X, Gleber-Netto FO, Rubin ML, Qing Y, et al
    Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection.
    Clin Cancer Res. 2022 Apr 20. pii: 694632. doi: 10.1158/1078-0432.CCR-21-3239.
    PubMed     Abstract available
    
    
    
84. FERRAROTTO R, Amit M, Nagarajan P, Rubin ML, et al
    Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck.
    Clin Cancer Res. 2022;28:1735.
    PubMed    
    
    
    
85. LEE AW, Ng WT, Choi CW, But B, et al
    Exploratory Study of NPC-0501 Trial - Optimal Cisplatin Dose of Concurrent and Induction/Adjuvant Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma.
    Clin Cancer Res. 2022 Apr 5. pii: 694221. doi: 10.1158/1078-0432.CCR-21-3375.
    PubMed     Abstract available
    
    
    
86. GUIX I, Liu Q, Pujana MA, Ha P, et al
    Validation of Anticorrelated TGFbeta Signaling and Alternative End-Joining DNA Repair Signatures that Predict Response to Genotoxic Cancer Therapy.
    Clin Cancer Res. 2022;28:1372-1382.
    PubMed     Abstract available
    
    
    March 2022
87. CHUNG CH, Li J, Steuer CE, Bhateja P, et al
    Phase II multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and/or metastatic head and neck squamous cell carcinoma.
    Clin Cancer Res. 2022 Mar 28. pii: 694028. doi: 10.1158/1078-0432.CCR-21-3849.
    PubMed     Abstract available
    
    
    
88. OKADA M, Kato K, Cho BC, Takahashi M, et al
    Three-year follow-up and response-survival relationship of nivolumab in previously treated patients with advanced esophageal squamous cell carcinoma (ATTRACTION-3).
    Clin Cancer Res. 2022 Mar 16. pii: 682194. doi: 10.1158/1078-0432.CCR-21-0985.
    PubMed     Abstract available
    
    
    
89. RICKELT S, Neyaz A, Condon C, Whittaker CA, et al
    Agrin Loss in Barrett's Esophagus-Related Neoplasia and Its Utility as a Diagnostic and Predictive Biomarker.
    Clin Cancer Res. 2022;28:1167-1179.
    PubMed     Abstract available
    
    
    
90. OBRADOVIC A, Graves D, Korrer M, Wang Y, et al
    Immunostimulatory cancer-associated fibroblast subpopulations can predict immunotherapy response in head and neck cancer.
    Clin Cancer Res. 2022 Mar 9. pii: 682113. doi: 10.1158/1078-0432.CCR-21-3570.
    PubMed     Abstract available
    
    
    February 2022
91. WISE-DRAPER TM, Gulati S, Palackdharry S, Hinrichs BH, et al
    Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2022 Feb 28:OF1-OF8. doi: 10.1158/1078-0432.CCR-21-3351.
    PubMed     Abstract available
    
    
    
92. XU Y, Dong B, Zhu W, Li J, et al
    A phase III multicenter randomized clinical trial of 60 Gy vs 50 Gy radiation dose in concurrent chemoradiotherapy for inoperable esophageal squamous cell carcinoma.
    Clin Cancer Res. 2022 Feb 18. pii: 681705. doi: 10.1158/1078-0432.CCR-21-3843.
    PubMed     Abstract available
    
    
    
93. SACCO AG, Cohen EEW
    Inevitable Progress-Relying on the Immune System, Not Chance.
    Clin Cancer Res. 2022;28:435-437.
    PubMed     Abstract available
    
    
    January 2022
94. FERRIS RL, Moskovitz J, Kunning S, Ruffin AT, et al
    Phase I trial of cetuximab, radiation therapy, and ipilimumab in locally advanced head and neck cancer.
    Clin Cancer Res. 2022 Jan 28. pii: 1078-0432.CCR-21-0426.
    PubMed     Abstract available
    
    
    
95. KAO HF, Liao BC, Huang YL, Huang HC, et al
    Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis.
    Clin Cancer Res. 2022 Jan 19. pii: 1078-0432.CCR-21-3025.
    PubMed     Abstract available
    
    
    
96. LI Y, Yang X, Du X, Lei Y, et al
    Correction: RAB37 Hypermethylation Regulates Metastasis and Resistance to Docetaxel-Based Induction Chemotherapy in Nasopharyngeal Carcinoma.
    Clin Cancer Res. 2022;28:430.
    PubMed    
    
    
    
97. CAO Y, Haring CT, Brummel C, Bhambhani C, et al
    Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma.
    Clin Cancer Res. 2022;28:350-359.
    PubMed     Abstract available
    
    
    December 2021
98. WEBER P, Kunstner A, Hess J, Unger K, et al
    Therapy-related transcriptional subtypes in matched primary and recurrent head and neck cancer.
    Clin Cancer Res. 2021 Dec 29. pii: 1078-0432.CCR-21-2244.
    PubMed     Abstract available
    
    
    
99. COHEN EEW, Nabell L, Wong DJ, Day T, et al
    Intralesional SD-101 in combination with pembrolizumab in anti-PD-1 treatment naive head and neck squamous cell carcinoma: results from a multicenter, phase 2 trial.
    Clin Cancer Res. 2021 Dec 29. pii: 1078-0432.CCR-21-1411.
    PubMed     Abstract available
    
    
    
100. LUGINBUHL AJ, Johnson JM, Harshyne LA, Linnenbach AJ, et al
     Tadalafil enhances immune signatures in response to neoadjuvant nivolumab in resectable head and neck squamous cell carcinoma.
     Clin Cancer Res. 2021 Dec 15. pii: 1078-0432.CCR-21-1816.
     PubMed     Abstract available
     
     
     
101. YAP TA, Vieito M, Baldini C, Sepulveda-Sanchez JM, et al
     First-In-Human Phase I Study of a Next-Generation, Oral, TGFbeta Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer.
     Clin Cancer Res. 2021;27:6666-6676.
     PubMed     Abstract available
     
     
     
102. PANG J, Nguyen N, Luebeck J, Ball L, et al
     Extrachromosomal DNA in HPV-Mediated Oropharyngeal Cancer Drives Diverse Oncogene Transcription.
     Clin Cancer Res. 2021;27:6772-6786.
     PubMed     Abstract available
     
     
     
103. TAYLOR MH, Betts CB, Maloney L, Nadler E, et al
     Safety and Efficacy of Pembrolizumab in Combination With Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study.
     Clin Cancer Res. 2021 Dec 3. pii: 1078-0432.CCR-21-2547.
     PubMed     Abstract available
     
     
     
104. SIRAVEGNA G, O'Boyle CJ, Varmeh S, Queenan N, et al
     Cell free HPV DNA provides an accurate and rapid diagnosis of HPV-associated head and neck cancer.
     Clin Cancer Res. 2021 Dec 2. pii: 1078-0432.CCR-21-3151.
     PubMed     Abstract available
     
     
     
105. EVEN C, Wang HM, Li SH, Ngan RK, et al
     Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer.
     Clin Cancer Res. 2021;27:6413-6423.
     PubMed     Abstract available
     
     
     November 2021
106. KATABATHULA R, Joseph P, Singh S, Zhao S, et al
     Multi-scale Pan-cancer Integrative Analyses Identify the STAT3-VSIR Axis as a key Immunosuppressive Mechanism in Head and Neck Cancer.
     Clin Cancer Res. 2021 Nov 16. pii: 1078-0432.CCR-21-1978.
     PubMed     Abstract available
     
     
     
107. BICKETT TE, Knitz M, Darragh LB, Bhatia S, et al
     FLT3L Release by Natural Killer Cells Enhances Response to Radioimmunotherapy in Preclinical Models of HNSCC.
     Clin Cancer Res. 2021;27:6235-6249.
     PubMed     Abstract available
     
     
     
108. LEUNG E, Han K, Zou J, Zhao Z, et al
     HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA.
     Clin Cancer Res. 2021;27:5857-5868.
     PubMed     Abstract available
     
     
     October 2021
109. HANNA GJ, ONeill A, Shin KY, Wong K, et al
     Neoadjuvant and adjuvant nivolumab and lirilumab in patients with recurrent, resectable squamous cell carcinoma of the head and neck.
     Clin Cancer Res. 2021 Oct 19. pii: 1078-0432.CCR-21-2635.
     PubMed     Abstract available
     
     
     September 2021
110. ZHANG JX, Chen ZH, Xu Y, Chen JW, et al
     Correction: Downregulation of MicroRNA-644a Promotes Esophageal Squamous Cell Carcinoma Aggressiveness and Stem Cell-like Phenotype via Dysregulation of PITX2.
     Clin Cancer Res. 2021;27:4942.
     PubMed    
     
     
     
111. DE LA IGLESIA JV, Slebos RJC, Martin-Gomez L, Wang X, et al
     Correction: Effects of Tobacco Smoking On the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma.
     Clin Cancer Res. 2021;27:4941.
     PubMed    
     
     
     August 2021
112. VYAS A, Harbison RA, Faden DL, Kubik M, et al
     Recurrent human papillomavirus-related head and neck cancer undergoes metabolic re-programming and is driven by oxidative phosphorylation.
     Clin Cancer Res. 2021 Aug 18. pii: 1078-0432.CCR-20-4789.
     PubMed     Abstract available
     
     
     
113. XIA WX, Lv X, Liang H, Liu GY, et al
     A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer.
     Clin Cancer Res. 2021;27:4186-4194.
     PubMed     Abstract available
     
     
     July 2021
114. ZHENG X, Xu Z, Ji Q, Ge M, et al
     A randomized, phase 3 study of lenvatinib in Chinese patients with radioiodine-refractory differentiated thyroid cancer.
     Clin Cancer Res. 2021 Jul 29. pii: 1078-0432.CCR-21-0761.
     PubMed     Abstract available
     
     
     
115. BRAND TM, Hartmann S, Bhola NE, Peyser ND, et al
     Correction: Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV(+) Patients.
     Clin Cancer Res. 2021;27:4129.
     PubMed    
     
     
     
116. KARPINETS TV, Mitani Y, Liu B, Zhang J, et al
     Whole-Genome Sequencing of Common Salivary Gland Carcinomas: Subtype-Restricted and Shared Genetic Alterations.
     Clin Cancer Res. 2021;27:3960-3969.
     PubMed     Abstract available
     
     
     
117. CHENG NM, Yao J, Cai J, Ye X, et al
     Deep Learning for Fully Automated Prediction of Overall Survival in Patients with Oropharyngeal Cancer Using FDG-PET Imaging.
     Clin Cancer Res. 2021;27:3948-3959.
     PubMed     Abstract available
     
     
     
118. LABIANO S, Roh V, Godfroid C, Hiou-Feige A, et al
     CD40 Agonist Targeted to Fibroblast Activation Protein alpha Synergizes with Radiotherapy in Murine HPV-Positive Head and Neck Tumors.
     Clin Cancer Res. 2021;27:4054-4065.
     PubMed     Abstract available
     
     
     
119. DE CLERCQ NC, van den Ende T, Prodan A, Hemke R, et al
     Fecal Microbiota Transplantation from Overweight or Obese Donors in Cachectic Patients with Advanced Gastroesophageal Cancer: A Randomized, Double-blind, Placebo-Controlled, Phase II Study.
     Clin Cancer Res. 2021;27:3784-3792.
     PubMed     Abstract available
     
     
     June 2021
120. FERRAROTTO R, Amit M, Nagarajan P, Rubin ML, et al
     Pilot phase II trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck.
     Clin Cancer Res. 2021 Jun 29. pii: 1078-0432.CCR-21-0585.
     PubMed     Abstract available
     
     
     
121. BURGENER JM, Zou J, Zhao Z, Zheng Y, et al
     Tumor-Naive Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma.
     Clin Cancer Res. 2021 Jun 22. pii: 1078-0432.CCR-21-0110.
     PubMed     Abstract available
     
     
     
122. VAN DEN ENDE T, de Clercq NC, van Berge Henegouwen MI, Gisbertz SS, et al
     Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT).
     Clin Cancer Res. 2021;27:3351-3359.
     PubMed     Abstract available
     
     
     
123. PAPPA T, Ahmadi S, Marqusee E, Johnson HL, et al
     Oncogenic mutations in PI3K/AKT/mTOR pathway effectors associate with worse prognosis in BRAF(V600E)-driven papillary thyroid cancer patients.
     Clin Cancer Res. 2021 Jun 4. pii: 1078-0432.CCR-21-0874.
     PubMed     Abstract available
     
     
     
124. OPENSHAW MR, Pinato DJ, Valeri N
     Back from the Brink: EGFR Inhibition in Gastroesophageal Cancer.
     Clin Cancer Res. 2021;27:2964-2966.
     PubMed     Abstract available
     
     
     
125. HEGDE A, Jayaprakash P, Couillault CA, Piha-Paul S, et al
     A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies.
     Clin Cancer Res. 2021;27:3050-3060.
     PubMed     Abstract available
     
     
     
126. PENG Z, Wei J, Wang F, Ying J, et al
     Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
     Clin Cancer Res. 2021;27:3069-3078.
     PubMed     Abstract available
     
     
     
127. CORSO S, Pietrantonio F, Apicella M, Migliore C, et al
     Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas.
     Clin Cancer Res. 2021;27:3126-3140.
     PubMed     Abstract available
     
     
     May 2021
128. LEE RH, Kang H, Yom SS, Smogorzewska A, et al
     Treatment of Fanconi Anemia-Associated Head and Neck Cancer: Opportunities to Improve Outcomes.
     Clin Cancer Res. 2021 May 27. pii: 1078-0432.CCR-21-1259.
     PubMed     Abstract available
     
     
     
129. KIM J, Bradford D, Larkins E, Pai-Scherf LH, et al
     FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid cancers with RET gene mutations or fusions.
     Clin Cancer Res. 2021 May 27. pii: 1078-0432.CCR-21-0967.
     PubMed     Abstract available
     
     
     April 2021
130. LI D, Chi Y, Chen X, Ge MH, et al
     Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial.
     Clin Cancer Res. 2021 Apr 8. pii: 1078-0432.CCR-20-2950.
     PubMed     Abstract available
     
     
     
131. CATENACCI DVT
     A PERFECT biomarker-focused study of neoadjuvant IO for esophagogastric cancer.
     Clin Cancer Res. 2021 Apr 6. pii: 1078-0432.CCR-21-0324.
     PubMed     Abstract available
     
     
     
132. WAINBERG ZA, Fuchs CS, Tabernero J, Shitara K, et al
     Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score >/=10.
     Clin Cancer Res. 2021;27:1923-1931.
     PubMed     Abstract available
     
     
     March 2021
133. LEI M, Siemers NO, Pandya D, Chang H, et al
     Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab{plus minus}Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer.
     Clin Cancer Res. 2021 Mar 29. pii: 1078-0432.CCR-20-2790.
     PubMed     Abstract available
     
     
     
134. ZHAO M, Scott S, Evans KW, Yuca E, et al
     Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer.
     Clin Cancer Res. 2021;27:1681-1694.
     PubMed     Abstract available
     
     
     February 2021
135. KLEIN S, Quaas A, Quantius J, Loser H, et al
     Deep Learning Predicts HPV Association in Oropharyngeal Squamous Cell Carcinomas and Identifies Patients with a Favorable Prognosis Using Regular H&E Stains.
     Clin Cancer Res. 2021;27:1131-1138.
     PubMed     Abstract available
     
     
     
136. FERRAROTTO R, Mitani Y, McGrail DJ, Li K, et al
     Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets.
     Clin Cancer Res. 2021;27:852-864.
     PubMed     Abstract available
     
     
     January 2021
137. WATERMANN C, Pasternack H, Idel C, Ribbat-Idel J, et al
     Recurrent HNSCC Harbor an Immunosuppressive Tumor Immune Microenvironment Suggesting Successful Tumor Immune Evasion.
     Clin Cancer Res. 2021;27:632-644.
     PubMed     Abstract available
     
     
     December 2020
138. THAKUR S, Daley B, Millo C, Cochran C, et al
     (177)Lu-DOTA-EB-TATE, A Radiolabeled Analog of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer.
     Clin Cancer Res. 2020 Dec 22. pii: 1078-0432.CCR-20-3453.
     PubMed     Abstract available
     
     
     November 2020
139. BRADFORD D, Larkins E, Mushti SL, Rodriguez L, et al
     FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid cancers with RET Gene Mutations or Fusions.
     Clin Cancer Res. 2020 Nov 25. pii: 1078-0432.CCR-20-3558.
     PubMed     Abstract available
     
     
     September 2020
140. GRAY KD, McCloskey JE, Vedvyas Y, Kalloo OR, et al
     PD1 blockade enhances ICAM1-directed CAR T therapeutic efficacy in advanced thyroid cancer.
     Clin Cancer Res. 2020 Sep 4. pii: 1078-0432.CCR-20-1523.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Head and Neck Cancer is free of charge.